|
Posted on Thursday, July 12, 2012 11:25 PM
Children with Hodgkin lymphoma who have favorable clinical features and who respond early to chemotherapy may not need treatment with radiation. The finding, reported in the June 27JAMA, is from a clinical trial of 88 patients with low-risk disease.
Patients who had an early complete response to the chemotherapy regimen used in the trial and were not treated with radiation therapy (as stipulated in the study protocol) had 5-year survival rates similar to those of children who did not have the same response to chemotherapy and therefore required radiation. |
|
|
NCI: Posted on Thursday, May 31, 2012 4:03 PM
Preliminary results from a phase I clinical trial suggest that the targeted drug crizotinib (Xalkori) may be effective in children with cancer whose tumors harbor genetic alterations in the ALK gene. In some children, the drug caused all signs of the disease to disappear (complete response). Crizotinib is already approved by the Food and Drug Administration to treat patients with lung cancer whose tumors have ALK mutations. The findings were presented at a press briefing on May 16 in advance of the American Society of Clinical Oncology (ASCO) annual meeting . |
|
|
NCI: Posted on Wednesday, July 27, 2011 9:45 PM
"Last summer I was diagnosed with bilateral Avascular Necrosis in my hips from all of the prednisone I received throughout the years [of chemotherapy]. In the fall I had core decompression on my left hip and it was pretty useless in resolving my chronic bone pain.… Because of my age (21) my orthopedic surgeon does not want to perform hip replacement surgery and I feel like I'm sort of just stuck with the pain without any resolution." —Post on stupidcancer.com forumCataracts, hearing loss, chronic pain, amputation,
|
|
|
NCI: Posted on Wednesday, July 27, 2011 9:32 PM
If you are interested in information on adolescents and cancer read on:
The first scientific journal dedicated to cancers in adolescents and young adults (AYAs) published its first issue in March, marking a milestone for the emerging field of AYA oncology. But as experts noted in a roundtable discussion in the issue, the field faces many challenges, particularly when it comes to understanding the biology of these diseases.At one point in the conversation, Dr. Archie Bleyer of the St. Charles Regional Cancer Center in Bend, OR, shared a concern about the state of the science. |
|